default author photo

Gabriela Lenarczyk

University of Copenhagen - Centre for Advanced Studies in Bioscience Innovation Law (CeBIL)

Karen Blixens Plads 16

Copenhagen S, 2300

Denmark

SCHOLARLY PAPERS

6

DOWNLOADS

427

TOTAL CITATIONS

0

Scholarly Papers (6)

1.

The European Medicines Agency’s path to greater access to pharmaceutical regulatory data: balancing intellectual property rights and the right to privacy

Forthcoming in Kritika: Essays on Intellectual Property, Vol. 6 (Edward Elgar, 2024), Queen Mary Law Research Paper No. 422/2024
Number of pages: 34 Posted: 01 Feb 2024
Duncan Matthews, Gabriela Lenarczyk and Żaneta Zemła-Pacud
Queen Mary University of London - School of Law, University of Copenhagen - Centre for Advanced Studies in Bioscience Innovation Law (CeBIL) and The Institute of Law Studies at the Polish Academy of Sciences
Downloads 201 (386,064)

Abstract:

Loading...

Intellectual property, regulatory test data, clinical trial data, pharmaceutical products, confidentiality, human rights, Charter of Fundamental Rights of the European Union, European Medicines Agency

2.

Quantum Computing and Ethical Exceptionalism: Lessons from Classical Computing

Number of pages: 25 Posted: 08 Oct 2025 Last Revised: 17 May 2026
University of Copenhagen - Centre for Advanced Studies in Bioscience Innovation Law (CeBIL), LML, University of Cambridge, University of Copenhagen - Centre for Advanced Studies in Bioscience Innovation Law (CeBIL), University of Copenhagen - Centre for Advanced Studies in Bioscience Innovation Law (CeBIL), National University of Singapore (NUS) - Centre for Biomedical Ethics, University of Copenhagen - Centre for Advanced Studies in Bioscience Innovation Law (CeBIL) and University of Copenhagen - Centre for Advanced Studies in Bioscience Innovation Law (CeBIL)
Downloads 100 (689,572)

Abstract:

Loading...

quantum computing ethics, classical computing, quantum exceptionalism, security, justice, governance, human agency

3.

The nature, scope and validity of patent pledges

Journal of Intellectual Property Law & Practice, 2024, Vol. 19, No. 11, University of Cambridge Faculty of Law Research Paper No. 24/2025
Number of pages: 5 Posted: 22 Dec 2025 Last Revised: 19 Feb 2026
Gabriela Lenarczyk, Timo Minssen and Mateo Aboy
University of Copenhagen - Centre for Advanced Studies in Bioscience Innovation Law (CeBIL), University of Copenhagen - Centre for Advanced Studies in Bioscience Innovation Law (CeBIL) and LML, University of Cambridge
Downloads 35 (1,263,436)

Abstract:

Loading...

patents, intellectual property law, vaccines, EU, patent pledges, Moderna

4.

OpenAI’s Patent Pledge: A Post-Moderna Analysis

University of Cambridge Faculty of Law Research Paper No. 26/2025, Journal of Intellectual Property Law and Practice, volume 20, issue 6, 2025[10.1093/jiplp/jpaf006]
Number of pages: 7 Posted: 22 Dec 2025 Last Revised: 23 Dec 2025
Gabriela Lenarczyk and Mateo Aboy
University of Copenhagen - Centre for Advanced Studies in Bioscience Innovation Law (CeBIL) and LML, University of Cambridge
Downloads 34 (1,290,922)

Abstract:

Loading...

patent pledges, vaccines, innovation, intellectual property law, OpenAI

5.

Upstream Disclosure, Downstream Assurance: EHDS Article 78 as a Compliance Pathway for AI Act Article 10 in Medical AI

Number of pages: 22 Posted: 11 May 2026
Peter Alexander Earls Davis, Gabriela Lenarczyk and Mateo Aboy
University of Copenhagen - Centre for Advanced Studies in Bioscience Innovation Law (CeBIL), University of Copenhagen - Centre for Advanced Studies in Bioscience Innovation Law (CeBIL) and LML, University of Cambridge
Downloads 32 (1,385,945)

Abstract:

Loading...

EU AI Act, European Health Data Space, Data Governance, Medical AI, GDPR, Bias Mitigation, Secondary Use

6.

The Promose if the EU's Draft Repurposing Programme 

Number of pages: 42 Posted: 19 Jun 2026
John Liddicoat and Gabriela Lenarczyk
King’s College London and University of Copenhagen - Centre for Advanced Studies in Bioscience Innovation Law (CeBIL)
Downloads 25

Abstract:

Loading...

drug repurposing, empirical data, European Medicines Agency (EMA), government programme, law reform, off-label use